Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NRIX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNurix lands up to $2.3B Roche deal for bexobrutideg, receives $700M upfront
Filed July 9, 2026 · Period ending July 9, 2026 · ~1 min read
Key Changes
-
high
Nurix entered a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, receiving $700M upfront (within 30 days of closing) with potential total payments up to $2.3B including milestones.
Exhibit 99.1 view on EDGAR → -
high
Companies will share U.S. development costs 40/60 (Nurix/Roche) and U.S. profits equally; Nurix receives tiered royalties on ex-U.S. sales across hematology, immunology, and neurology indications.
Exhibit 99.1 view on EDGAR → -
high
Pro-forma cash position expected to reach approximately $1.14B including the expected $700M upfront payment, up from $443.5M as of May 31, 2026.
Exhibit 99.1 view on EDGAR → -
high
Updated bexobrutideg Phase 1a data showed 22.1-month median progression-free survival and 83% response rate in relapsed/refractory CLL/SLL; Phase 1b showed 92.9% response in BTKi-experienced patients and 84.2% in BTKi-naïve patients.
Exhibit 99.1 view on EDGAR → -
medium
Q2 2026 revenue fell to $9.0M from $44.1M year-over-year (prior year included $30M in Sanofi license revenue); net loss widened to $89.5M ($0.81/share) from $43.5M ($0.52/share) as R&D spending increased to $87.7M.
Exhibit 99.1 view on EDGAR →
Summary
Nurix Therapeutics announced a transformative collaboration with Roche for its BTK degrader bexobrutideg, securing $700 million upfront and potential total payments up to $2.3 billion. The deal validates Nurix's lead asset with strong clinical data presented at EHA 2026, including durable responses across difficult-to-treat CLL/SLL patient populations. Roche will shoulder 60% of U.S. development costs while Nurix retains equal U.S. profit-sharing and ex-U.S. royalties, a structure that preserves meaningful economics while de-risking the path to commercialization.
The upfront payment more than doubles Nurix's cash position to approximately $1.14 billion pro-forma, providing runway to advance bexobrutideg into Phase 3 trials and fund the company's broader pipeline. The collaboration covers multiple indications beyond hematology, including immunology and neurology, expanding the commercial opportunity. For retail holders, this deal represents a major inflection point: Nurix transitions from a cash-constrained clinical-stage company to a well-capitalized partner of a global pharma, with validation of its protein degradation platform and a clear path to potential commercialization.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Revenue for the three months ended May 31, 2026, was $9.0 million compared with $44.1 million for the three months ended May 31, 2025. The decrease was primarily due to $30 million of license revenue from two Sanofi license extensions in the prior year. During the three months ended May 31, 2026, Nurix achieved a research milestone under its collaboration with Sanofi of $2 million. ... Net loss for the three months ended May 31, 2026, was $89.5 million or ($0.81) per share compared with $43.5 million or ($0.52) per share for the three months ended May 31, 2025. ... Cash, cash equivalents and marketable securities were $443.5 million as of May 31, 2026, compared to $592.9 million as of November 30, 2025.
Nurix reported Q2 2026 revenue of $9.0 million, down from $44.1 million in Q2 2025, primarily due to $30 million in Sanofi license revenue in the prior year. Net loss widened to $89.5 million ($0.81 per share) from $43.5 million ($0.52 per share) in Q2 2025. Cash, cash equivalents, and marketable securities totaled $443.5 million as of May 31, 2026, down from $592.9 million at November 30, 2025.
Added in current filing · view on EDGAR →
Research and development expenses for the three months ended May 31, 2026, were $87.7 million compared with $78.1 million for the three months ended May 31, 2025. The increase was primarily related to clinical costs and contract manufacturing costs as Nurix continued to accelerate the enrollment of patients in the ongoing Phase 2 trial of bexobrutideg and to enable the initiation of Phase 3 trials.
R&D expenses increased to $87.7 million in Q2 2026 from $78.1 million in Q2 2025, driven by clinical costs and contract manufacturing as Nurix accelerated enrollment in the Phase 2 bexobrutideg trial and prepared for Phase 3 trial initiation.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 10, 2026 · How we verify